FIGURE 5.

Effect of MEDI1814 on CSF Aβ biomarkers after single and multiple dose administration to patients with AD. Data show percentage change from baseline to follow‐up day 29 in CSF levels of (A), free Aβ₄₂, (B) total Aβ₄₂, and (C) total Aβ₄₀ after single doses of placebo or MEDI1814 (25, 100, 300, 900, and 1800 mg IV or 100 mg SC). Median and individual data points are shown for % change from baseline. Free Aβ₄₂ in CSF was greatly reduced in the highest dose cohorts (300–1800 mg IV), but lower levels of suppression were observed for the lower doses (100 mg IV, 100 mg SC, and 25 mg IV), compared to placebo. All individual data with median values shown where baseline and post‐dose sample available. Data are pooled for the placebo group after single dosing across the dose range. Data are pooled for the placebo groups after multiple dosing according to administration (IV or SC). Green symbol – Aβ42 free data at LLOQ (single ascending dose = 32 pg/mL; multiple ascending dose = 12 pg/mL). Aβ, amyloid beta; AD, Alzheimer's disease; CSF, cerebrospinal fluid; IV, intravenous; LLOQ, lower limit of quantification; MAD, multiple ascending dose; SC, subcutaneous.